Since my previous article on Banc of California ( BANC ) was published, I was able to pick up some of the bank's preferred shares at a discount to its par value. As I now have a long position in The Investment Doctor is a financial writer, highlighting European small-caps with a 5-7 year investment horizon. He strongly believes a portfolio should consist of a mixture of dividend and growth stocks. He is the leader of the investment group European Small Cap Ideas which offers exclusive access to actionable r ...

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Paysafe Limited (NYSE:PSFE) and StubHub Holdings, Inc. (NYSE:STUB). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided. Paysafe Limited (NYSE:PSFE) On November 13, 2025, Paysaf ...

Thousands of Microsoft workers have been laid off in the past year, and Washington resident Mike Kostersitz is just one of them. After spending 31 years at Microsoft, he's now looking for a job for the first time in more than three decades. Must Read In May, the 60-year-old principal product manager lead said a new high-priority meeting appeared on his calendar out of nowhere. "Me and 120 other anonymous faces got told our jobs had been eliminated," he told Business Insider (1). The layoff came as a complet ...

Core Insights - It is emphasized that starting an investment journey is always possible, particularly for beginners [1] Group 1 - Investing in exchange-traded funds (ETFs) is highlighted as a beneficial choice for novice investors [1]

Byju Raveendran, the embattled founder of Indian ed-tech giant Byju's, has blasted a U.S. bankruptcy court's order directing him to pay more than $1.07 billion. He is denying wrongdoing, accusing lenders of misleading the court, and vowing to appeal a ruling that marks a dramatic fall for a onetime poster boy of India's startup boom. The Delaware bankruptcy judge issued a default judgment after finding that Raveendran had repeatedly ignored court orders and provided "evasive, incomplete" responses regarding ...

Core Points - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Jayud Global Logistics Ltd. for the period between April 21, 2023, and April 30, 2025 [1] - Investors who purchased Jayud securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A lead plaintiff must move the Court by January 20, 2026, to represent other class members in the litigation [3] Case Details - The lawsuit alleges that Jayud made materially false and misleading statements and failed to disclose critical information, including involvement in a fraudulent stock promotion scheme and insider trading activities [5] - Specific allegations include the use of social media misinformation, offshore accounts for share dumping, and omission of false rumors affecting stock prices [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as Rosen Law Firm has achieved significant settlements in the past [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]

Key Points When it comes to artificial intelligence (AI) stocks, the semiconductor industry is one of the most closely followed. Parallel processors from chip designers like Nvidia, Advanced Micro Devices, and Broadcom have become the hardware backbone of generative AI. Meanwhile, Taiwan Semiconductor Manufacturing remains perhaps the most lucrative pick-and-shovel AI trade in the market given its leading position in the chip fabrication space. Another chip stock that has put on an impressive show throughou ...

Core Viewpoint - The media's focus on generating emotional responses has led to a distortion of factual data, particularly regarding generational narratives and housing market trends [3][4][5]. Group 1: Intergenerational Narratives - Recent media narratives suggest that baby boomers are blocking younger generations from homeownership, with claims that the median age of first-time homebuyers has risen to 40 [5]. - However, alternative research from the Census Bureau and Federal Reserve indicates that the actual median age of first-time homebuyers is 36, which is lower than in previous decades [6][8]. - The discrepancy arises from the methodology used by the National Association of Realtors (NAR), which relied on mail surveys that skewed results due to low response rates [7]. Group 2: Market Sentiment and Indicators - The CNN Fear and Greed Index shows that average investor sentiment is currently fearful, despite stock performance being up approximately 13.5% over the past year [12]. - The discount to net asset value (NAV) for closed-end funds (CEFs) is around 5.3%, which is narrower than the long-term average of about 7%, indicating that fear in the media is not leading to significant selling pressure [13][14]. - This suggests that media narratives do not accurately reflect actual market sentiment and investor behavior [15].

Core Insights - Eli Lilly's stock has increased by 36% this year, achieving a market capitalization of $1 trillion, marking it as the first healthcare company to reach this milestone [2][3] - The stock's rise is attributed to strong growth expectations, particularly from its diabetes and weight loss drugs, and a deal to lower drug prices [3][14] - Analysts suggest it may not be too late for investors to consider Eli Lilly [3] Financial Performance - Eli Lilly's Q3 revenue grew by 54% to $17.6 billion, exceeding estimates by approximately $1.5 billion [14] - Adjusted earnings per share reached $7.02, surpassing consensus estimates by over $1 [14] - The company raised its revenue and EPS guidance for 2025 to $63.25 billion and about $22 per share, respectively [14] Market Position - Eli Lilly holds a dominant position in the diabetes and weight loss drug market, controlling about 57% of the U.S. market for incretins [6] - The market for diabetes and weight loss drugs is projected to reach $150 billion by the early 2030s [6] - Mounjaro and Zepbound, two of Lilly's key products, have seen significant sales growth, with Mounjaro's revenue increasing by 68% to $5.2 billion and Zepbound's sales rising by 172% to nearly $3.4 billion [7][15] Innovation and Future Growth - Eli Lilly's innovation pipeline includes potential new treatments, such as retatrutide for obesity, expected to report positive trial results in late 2025 [8] - The company has also received FDA approval for an Alzheimer's therapy named Kisunla, which could contribute to future revenue [8] - The success of Eli Lilly's products is attributed to their clinical effectiveness and faster scaling of manufacturing compared to competitors [10][12] Competitive Landscape - Eli Lilly's Mounjaro has outperformed Novo Nordisk's Ozempic in treating both diabetes and weight loss, contributing to its market leadership [10][11] - The competitive advantage stems from Mounjaro's ability to target multiple gut hormones, unlike Novo Nordisk's treatments [10][11] Future Projections - Analysts predict a 30% chance that Eli Lilly's market capitalization could double by 2028 if its innovation pipeline is successful [4] - However, there is a 20% chance that the stock could lose 30% of its value due to price competition and regulatory challenges [4] - Wall Street consensus views the stock as slightly overvalued, with an average price target indicating a 2% overvaluation [18]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Hormel Foods Corporation due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a Wall Street Journal article published on October 29, 2025, which reported that Hormel Foods cut its earnings forecast due to price pressures, bird flu, and a fire at its Arkansas peanut butter production facility [3]. - Following the news, Hormel Foods' stock experienced a significant decline of 9.1% on the same day [3]. Group 2: Class Action Information - Shareholders who purchased Hormel securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].